


IRAK4-IN-6

Cat. No.:	HY-130253		
CAS No.:	2454244-02-9		
Molecular Formula:	C ₂₅ H ₃₂ N ₁₀ O ₂		
Molecular Weight:	504.59		
Target:	IRAK		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (247.73 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		1.9818 mL	9.9090 mL	19.8181 mL
		5 mM		0.3964 mL	1.9818 mL	3.9636 mL
10 mM		0.1982 mL	0.9909 mL	1.9818 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.12 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.12 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC ₅₀ of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma ^[1] .
IC ₅₀ & Target	IC50: 4 nM (IRAK4) ^[1]

REFERENCES

[1]. Degorce SL, et al. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma. J Med Chem. 2019 Nov 1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA